v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue:        
Total revenue $ 12,669 $ 889 $ 24,308 $ 2,646
Operating expenses:        
Research and development 71,888 58,902 207,614 201,280
Acquired in-process research and development 11,675 0 14,148 96,253
General and administrative 17,867 16,931 52,603 55,143
Collaboration expense, net 41,284 57,115 127,505 159,777
Total operating expenses 142,714 132,948 401,870 512,453
Loss from operations (130,045) (132,059) (377,562) (509,807)
Other income:        
Other income, net 18,682 26,237 53,913 61,841
Total other income, net 18,682 26,237 53,913 61,841
Net loss before income taxes (111,363) (105,822) (323,649) (447,966)
Provision for income taxes (74) (619) (1,873) (3,020)
Net loss (111,437) (106,441) (325,522) (450,986)
Foreign currency translation adjustment 2 (28) (20) 94
Unrealized (loss) gain on marketable securities (9,456) 973 (18,884) 3,052
Comprehensive loss $ (120,891) $ (105,496) $ (344,426) $ (447,840)
Net loss per common share - basic $ (1.15) $ (1.17) $ (3.38) $ (5.12)
Basic weighted-average common shares outstanding 96,741,070 91,305,337 96,437,995 88,124,241
Net loss per common share - diluted $ (1.15) $ (1.17) $ (3.38) $ (5.12)
Diluted weighted-average common shares outstanding 96,741,070 91,305,337 96,437,995 88,124,241
Collaboration Revenue [Member]        
Revenue:        
Total revenue $ 12,323 $ 0 $ 23,323 $ 0
Grant Revenue [Member]        
Revenue:        
Total revenue $ 346 $ 889 $ 985 $ 2,646